SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CG Oncology, Inc. Common stock (CGON) has a negative trailing P/E of -32.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 141.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.05%, forward earnings yield 0.71%. PEG 0.52 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (41/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 141.3 — analysts expect a return to profitability with estimated EPS of $0.48 for FY2028.
- PEG Ratio 0.52 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -3.05% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.71% as earnings recover.
- Analyst consensus target $79.00 (+17.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
41/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CGON
Valuation Multiples
P/E (TTM)-32.8
Forward P/E141.3
PEG Ratio0.52
Forward PEG0.52
P/B Ratio7.02
P/S Ratio1,428.10
EV/EBITDA-34.3
Per Share Data
EPS (TTM)$-2.08
Forward EPS (Est.)$0.48
Book Value / Share$9.74
Revenue / Share$0.05
FCF / Share$-1.71
Yields & Fair Value
Earnings Yield-3.05%
Forward Earnings Yield0.71%
Dividend Yield0.00%
Analyst Target$79.00 (+17.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2021 |
-192.9 |
0.00 |
61.53 |
239.13 |
- |
| 2022 |
-69.9 |
-0.51 |
19.79 |
12,967.90 |
- |
| 2023 |
-51.0 |
-0.93 |
13.40 |
12,141.52 |
- |
| 2024 |
-20.4 |
-0.53 |
2.44 |
1,573.67 |
- |
| 2025 |
-19.9 |
-0.42 |
4.26 |
794.47 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2021 |
$-0.19 |
$10.36M |
$-12.84M |
-124% |
| 2022 |
$-0.53 |
$191K |
$-35.44M |
-18556.5% |
| 2023 |
$-0.73 |
$204K |
$-48.61M |
-23827% |
| 2024 |
$-1.41 |
$1.14M |
$-88.04M |
-7729.5% |
| 2025 |
$-2.08 |
$4.04M |
$-161M |
-3985% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-2.40 |
$-3.01 – $-2.03 |
$14.31M |
$2.2M – $38.51M |
11 |
| 2027 |
$-2.01 |
$-3.19 – $-0.25 |
$140.6M |
$80.19M – $223.05M |
10 |
| 2028 |
$0.46 |
$-2.05 – $4.56 |
$482.32M |
$482.31M – $482.32M |
10 |
| 2029 |
$3.22 |
$0.46 – $9.04 |
$907.99M |
$308.36M – $2.17B |
4 |
| 2030 |
$6.52 |
$0.92 – $18.31 |
$1.43B |
$486.81M – $3.43B |
4 |
